# Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients

> **NCT01838395** · PHASE2 · COMPLETED · sponsor: **BioLineRx, Ltd.** · enrollment: 42 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Ara-C
- **DRUG:** BL-8040

## Key facts

- **NCT ID:** NCT01838395
- **Lead sponsor:** BioLineRx, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2016-03
- **Final completion:** 2023-07-20
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01838395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01838395, "Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT01838395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*